Phaseline

Companies › Zhejiang Yangli Pharmaceutical Technology

Zhejiang Yangli Pharmaceutical Technology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular, Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VB15010
PARP1 inhibitor
PARP1Phase 1Cancer–
VB19055–Phase 1Hypertension–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06819215VB15010Phase 1CancerOncologyDec 2025
NCT07254481VB19055Phase 1HypertensionCardiovascularJul 2026

Targets

PARP1 (1)

Companies with the same targets

AstraZeneca Eikon Therapeutics Haisco Pharmaceutical Group Hangzhou SynRx Therapeutics Biomedical Technology Merck & Co. (MSD) Nerviano Medical Sciences Pfizer Johnson & Johnson (Janssen) Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.